文献
J-GLOBAL ID:202002273814554554
整理番号:20A2684743
クッシング病以外の内因性クッシング症候群の日本人患者を対象とした,新規11β-ヒドロキシラーゼ阻害剤,オシロドロスタットの有効性と安全性を評価する多施設共同第2相試験
A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing’s syndrome other than Cushing’s disease
著者 (9件):
Tanaka Tomoaki
(Department of Molecular Diagnosis, Chiba University Hospital/Chiba University Graduate School of Medicine, Chiba 260-8670, Japan)
,
Satoh Fumitoshi
(Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Hospital, Sendai 980-8574, Japan)
,
Ujihara Makoto
(Department of Internal Medicine, National Hospital Organization Yokohama Medical Center, Yokohama 245-8575, Japan)
,
Midorikawa Sanae
(Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan)
,
Kaneko Tomomi
(Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan)
,
Takeda Tamami
(Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan)
,
Suzuki Akina
(Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan)
,
Sato Masahiko
(Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan)
,
Shimatsu Akira
(Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555/Advanced Medical Care Center, Kusatsu General Hospital, Kusatsu 525-8585, Japan)
資料名:
Endocrine Journal (Web)
(Endocrine Journal (Web))
巻:
67
号:
8
ページ:
841-852(J-STAGE)
発行年:
2020年
JST資料番号:
U1479A
ISSN:
1348-4540
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
日本 (JPN)
言語:
英語 (EN)